Signal52

FOLD

Featured Pick

Amicus Therapeutics, Inc.

Real picks. Real tracking. We bet on one stock daily and show you exactly how it plays out.

AI Confidence Score
85
Entry Price
$14.37
Current Price
$37.69
Total Return
+0.00%
vs SPY
+0.00%
As of Close 2026-03-11

Executive Summary

Amicus Therapeutics (FOLD) presents a compelling idiosyncratic opportunity insulated from current geopolitical macro risks, driven by its pending $4.8 billion all-cash acquisition by BioMarin at $14.50 per share. With shareholders overwhelmingly approving the merger earlier this month, the stock is experiencing intense upside pressure as a classic Squeeze Play. This setup perfectly aligns with the current CAUTION regime's flight-to-quality, offering an anchored valuation that ignores the broader market's Middle East volatility.

Technical Context

Setup
The stock is pressing directly against its 52-week high (just -0.1% away) with a market-leading confluence score of 16.0 and strong volume confirmation at 1.4x its 20-day average.
Invalidation (Stop)
The bullish thesis is invalidated if shares break below the hard support level of $14.30, which would signal an unexpected breakdown in the merger arbitrage spread.

Runner-ups

TKOStrong $1B buyback catalyst, but news is 38h old and the stock is lagging 10% off its 52-week high.
ALEXMerger approval provides certainty with high volume, but the 2026 closing date dilutes immediate momentum.

Recent Performance History

26 Total Picks • 57% Win Rate (7d)
DateTickerEntryLastGain/Loss7d30d60d
2026-03-10ALEX$20.83$20.83+0.00%N/AN/AN/A
2026-03-09EMD$10.36$10.50+1.35%N/AN/AN/A
2026-03-06DHIL$172.54$173.19+0.38%N/AN/AN/A
2026-03-05FOLD$14.33$14.37+0.28%N/AN/AN/A
2026-02-24AES$16.27$14.23-12.54%-12.60%N/AN/A
2026-02-23PRA$24.40$24.53+0.53%+0.98%N/AN/A
2026-02-20ST$38.35$35.38-7.74%-10.72%N/AN/A
2026-02-19FTI$61.76$64.38+4.24%+4.34%N/AN/A
2026-02-18FOLD$14.34$14.37+0.21%-0.07%N/AN/A
2026-02-17ROL$60.08$56.08-6.66%+0.72%N/AN/A
Schema v1.0 | Pipeline v1.2.0